Liver Transplantation for Nijmegen Breakage Syndrome With Hepatic Malignancy and Hepatopulmonary Syndrome After Bone Marrow Transplantation: A Case Report.
Nijmegen breakage syndrome
genomic instability
hepatic malignancy
intermediate cell carcinoma
liver transplantation
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Nov 2024
Nov 2024
Historique:
revised:
13
07
2024
received:
07
03
2024
accepted:
19
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
ppublish
Résumé
Nijmegen breakage syndrome (NBS) is an autosomal recessive DNA repair disorder that manifests through increased genomic instability, malignancy, and cellular and humoral immunodeficiencies. The prognosis for NBS patients is poor due to their increased susceptibility to fatal infections and lymphoproliferative malignancies. Currently, there is no specific treatment for NBS, though allogeneic hematopoietic stem cell transplantation (HSCT) has been performed and documented as case series to demonstrate the utility of transplantation. A 14-year-old girl with NBS and haploidentical HSCT from her older brother due to recurrent lung infection was referred for liver transplantation (LT) due to liver cirrhosis, hepatopulmonary syndrome (HPS), and suspicion of liver malignancy. It was decided to perform LT using the living donor who had previously donated for HSCT. Living donor left lobe LT was successfully performed from her brother. The patient experienced no complications in the early postoperative period and was discharged on the seventh postoperative day. Pathological examination of extracted liver has shown "intermediate cell carcinoma" in two foci. After 1 year LT, the patient has had an uneventful course in terms of LT complications and infection, with minimal immunosuppression. NBS patients have an increased prevalence of malignancies, including primary hepatic malignancy, but most are managed medically or with limited resections. Transplantation in these patients can be curative for hepatic malignancy with a favorable safety profile.
Sections du résumé
BACKGROUND
BACKGROUND
Nijmegen breakage syndrome (NBS) is an autosomal recessive DNA repair disorder that manifests through increased genomic instability, malignancy, and cellular and humoral immunodeficiencies. The prognosis for NBS patients is poor due to their increased susceptibility to fatal infections and lymphoproliferative malignancies. Currently, there is no specific treatment for NBS, though allogeneic hematopoietic stem cell transplantation (HSCT) has been performed and documented as case series to demonstrate the utility of transplantation.
METHODS
METHODS
A 14-year-old girl with NBS and haploidentical HSCT from her older brother due to recurrent lung infection was referred for liver transplantation (LT) due to liver cirrhosis, hepatopulmonary syndrome (HPS), and suspicion of liver malignancy. It was decided to perform LT using the living donor who had previously donated for HSCT.
RESULTS
RESULTS
Living donor left lobe LT was successfully performed from her brother. The patient experienced no complications in the early postoperative period and was discharged on the seventh postoperative day. Pathological examination of extracted liver has shown "intermediate cell carcinoma" in two foci. After 1 year LT, the patient has had an uneventful course in terms of LT complications and infection, with minimal immunosuppression.
CONCLUSIONS
CONCLUSIONS
NBS patients have an increased prevalence of malignancies, including primary hepatic malignancy, but most are managed medically or with limited resections. Transplantation in these patients can be curative for hepatic malignancy with a favorable safety profile.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14852Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
A. Antoccia, J. Kobayashi, H. Tauchi, S. Matsuura, and K. Komatsu, “Nijmegen Breakage Syndrome and Functions of the Responsible Protein, NBS1,” Genome Dynamics 1 (2006): 191–205.
R. Varon, I. Demuth, and K. H. Chrzanowska, “Nijmegen Breakage Syndrome,” in GeneReviews(®), eds. M. P. Adam, G. M. Mirzaa, R. A. Pagon, et al. (Seattle (washington, D.C.): University of Washington, Seattle, 1993).
B. Wolska‐Kusnierz, A. Pastorczak, W. Fendler, et al., “Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27 (2021): 575–584.
B. Wolska‐Kuśnierz and A. R. Gennery, “Hematopoietic Stem Cell Transplantation for DNA Double Strand Breakage Repair Disorders,” Frontiers in Pediatrics 7 (2019): 557.
Y. Wang, M. Li, J. Long, et al., “Clinical Significance of Increased Expression of Nijmegen Breakage Syndrome Gene (NBS1) in Human Primary Liver Cancer,” Hepatology International 8 (2014): 250–259.
A. Alim, B. Demir, A. Akbulut, C. Karataş, İ. Tırnova, and T. Kanmaz, “Liver Transplantation for Congenital Metabolic Disorders,” Cerrahpaşa Medical Journal 46 (2022): 21–25.
N. Bogdanova, S. Feshchenko, P. Schürmann, et al., “Nijmegen Breakage Syndrome Mutations and Risk of Breast Cancer,” International Journal of Cancer 122 (2008): 802–806.
R. Varon, A. Reis, H. Gn, E. HGv, K. Sperling, and K. J. C. Seeger, “Mutations in the Nijmegen Breakage Syndrome Gene (NBS1) in Childhood Acute Lymphoblastic Leukemia (ALL),” Cancer Research 61 (2001): 3570–3572.
R. Varon, I. Demuth, and K. H. Chrzanowska, Nijmegen Breakage Syndrome (Seattle (WA): University of Washington, Seattle, 1993).
Y. Yilmaz Demirdag and S. Gupta, “Infections in DNA Repair Defects,” Pathogens 12, no. 3 (2023): 440.
Y. Wang, Y. Hong, M. Li, et al., “Mutation Inactivation of Nijmegen Breakage Syndrome Gene (NBS1) in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma,” PLoS One 8 (2013): e82426.
V. Uygun, İ. Aliosmanoğlu, H. Daloğlu, et al., “Combined Haploidentical Hematopoetic Stem Cell Transplantation and Liver Transplantation in a Pediatric Patient,” International Journal of Hematology‐Oncology and Stem Cell Research 17 (2023): 291–295.
T. Shimizu, M. Kasahara, and K. Tanaka, “Living‐Donor Liver Transplantation for Chronic Hepatic Graft‐Versus‐Host Disease,” New England Journal of Medicine 354, no. 14 (2006): 1536–1537, https://doi.org/10.1056/NEJMc052628.
M. Mori, S. Tabata, H. Hashimoto, et al., “Successful Living Donor Liver Transplantation for Severe Hepatic GVHD Histologically Resembling Autoimmune Hepatitis After Bone Marrow Transplantation From the Same Sibling Donor,” Transplant International 23, no. 5 (2010): e1–e4, https://doi.org/10.1111/j.1432‐2277.2009.01028.x.
R. Handgretinger, A. M. Arendt, C. P. Maier, and P. Lang, “Ex Vivo and in Vivo T‐Cell Depletion in Allogeneic Transplantation: Towards Less or Non‐cytotoxic Conditioning Regimens,” Expert Review of Clinical Immunology 18 (2022): 1285–1296.